Illumina, Inc., BGI (A subsidiary of BGI Group), and Thermo Fisher Scientific Inc. have Dominated the Global Next Generation Sequencing (NGS) Market in 2021

Global Next Generation Sequencing (NGS) Market is expected to grow with the CAGR of 17.1% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-next-generation-sequencing-ngs-market

Global next generation sequencing (NGS) market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global next generation sequencing (NGS) market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

Next Generation Sequencing (NGS) Market

For instance:

  • In March 2020, Agilent Technologies, Inc. launched three new microarrays to address the requirements of prenatal and postnatal research in cytogenetic laboratories. These new product launched by the company increases its NGS product portfolio leading to increased demand for its products in future.

Illumina, Inc. is the dominating player in global next generation sequencing (NGS) market. The other key players existing in the market are Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., QIAGEN, Bio-Rad Laboratories, Inc., Roche Sequencing (A subsidiary of F. Hoffman La Roche), BGI  (A subsidiary of BGI Group), Oxford Nanopore Technologies plc, MACROGEN CO., LTD., DNASTAR, Geneious, Partek, Incorporated, PerkinElmer Inc., Takara Bio Inc., bioMérieux SA, Pacific Biosciences of California, Inc.,  GENEWIZ, 10x Genomics, New England Biolabs, Hamilton Company and among others.

Illumina, Inc.

Illumina, Inc. headquartered in San Diego, U.S. and established in 1998. The company is focused on developing, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company has three business segments Consumables, Instruments, Service out of which consumables and instruments is focused segment. The company has few product categories Sequencing Kits, Microarray Kits, Clinical Research Products, In Vitro Diagnostic (IVD) Products, Informatics Products, Molecular Biology Reagents, Accessory Products, and Service & Training Products. Sequencing Kits is the focused category for the market.

For instance,

  • In August 2021, Illumina Inc. has acquired GRAIL to accelerate patient access to multi cancer early detection test and gene sequencing procedures. This has helped the company to increase its product portfolio

The company has wide presence across North America, Europe, Asia-Pacific, South America and Middle East and Africa.

BGI (A Subsidiary of BGI Group)

BGI (A Subsidiary of BGI Group) founded in the year 1999 headquarter in Shenzhen, China. The company is focused in supporting the human genome project and is actively participating in the field of cancer research, Bio-sustainability and personalized medicine through a variety of subsidiaries. The company has various product categories such as COVID-19 Solutions, Molecular Genetics, Sequencing Services, Mass Spec, and Pharma Solutions in which Sequencing Services is focused segment.

  • In July 2019, BGI requested the scientists around the world to join the FAW Genome Initiative for the purpose of developing translational research collaborations. These insights will allow for the development of more effective management and control strategies such as identifying pesticide tolerance mechanisms, producing new more effective pesticides or identifying other methods of control through better understanding the genetic architecture of the FAW.

The company has presence across North America, Europe, Asia-Pacific, Middle East and Africa and Latin America.

Thermo Fisher Scientific Inc. 

Thermo Fisher Scientific Inc. founded in the year 1956, headquartered in Massachusetts, U.S. The company focuses on accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories. The company has its business segments as life science solutions, analytical instruments, specialty diagnostics, laboratory products, and services and life science solutions is focused segment. The company has many product categories including life sciences, industrial & applied sciences, clinical diagnostics, lab solutions and digital solutions in which life sciences is market focused category.

  • In September 2021, Thermo Fisher Scientific Inc. announced that it has entered into partnership with AstraZeneca to develop NGS-based companion diagnostics. The NGS workflow includes multiple solutions for liquid biopsy testing and solid tumor biomarkers. This is expected to expand the company’s product portfolio.

The company has presence across North America, Europe, Asia-Pacific, South America and Middle East and Africa. The company has subsidiaries which includes, Thermo Electron North America LLC (U.S.), Fisher Scientific GmbH (Germany), Fisher Scientific Korea Ltd (Korea), Thermo Fisher Scientific Germany BV & Co KG (Germany), and Thermo Fisher Scientific K.K. (Japan) among others.